Debu Tripathy

74PUBLICATIONS
331CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersMidwifery not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (74)

|Sep 22, 2026
Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial.

|May 13, 2026
Ecotypes of triple-negative breast cancer in response to chemotherapy.

|Apr 22, 2026
Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.

|Apr 15, 2026
ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage.

|Mar 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results.

Rashmi K Murthy, Barbara J O'Brien, Donald A Berry

|Feb 12, 2026
Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors.

Jasmine S Sukumar, Akshara S Raghavendra, Sarah Pasyar

Pageof 13

Frequent Collaborators

21 joint publications

Naoto Ueno

15 joint publications

Akshara Singareeka-Raghavendra

9 joint publications

Bora Lim

8 joint publications

Gabriel N Hortobagyi